Not sure where to start? Try searching for your diagnosis above or visit the "Conditions" section.
Curated scientific studies about autoimmune diseases.
This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or a qualified healthcare provider before making any health decisions. Full Disclaimer
A case report describes two people with severe neuromyelitis optica who have stayed relapse-free for more than 15 years after a donor stem c...
Read More — Two Patients, One Rare Disease, 15 Years of Remission »Sirolimus, a decades-old transplant drug, just delivered the first rigorous, placebo-controlled proof that blocking a pathway called mTOR ca...
Read More — A 125-Year-Old Drug Gets Its First Real Lupus Trial »A donor-derived natural killer cell therapy produced a 71% response rate in patients with severe, treatment-resistant rheumatoid arthritis,...
Read More — An Off-the-Shelf Cell Therapy Goes Head-to-Head With CAR-T »A large international trial found that secukinumab (Cosentyx), a drug already used for psoriasis and several types of arthritis, helped roug...
Read More — Cosentyx Clears the Bar in Polymyalgia Rheumatica »Results from the Phase III METEOROID trial announced at the American Academy of Neurology Annual Meeting in April 2026 showed that satralizu...
Read More — Phase III METEOROID Trial: Satralizumab Reduces MOGAD Relapse Risk by 68%, Opening Path to First Approved Treatment for Condition That Includes ADEM »A new clinical tool developed from a four-hospital Chinese study can predict survival outcomes in patients with MDA5-positive dermatomyositi...
Read More — Multicenter Study Develops Prognostic Nomogram for MDA5-Positive Dermatomyositis with Lung Disease »A critical appraisal of a large cohort study finds that neurological complications in dermatitis herpetiformis are likely significantly unde...
Read More — Neurological Complications in Dermatitis Herpetiformis May Be Underestimated by Standard Registry Data »A landmark phase 3 trial has found that brepocitinib, an oral TYK2/JAK1 inhibitor, significantly improved a comprehensive measure of disease...
Read More — Brepocitinib Achieves First Positive Phase 3 Trial Result in Dermatomyositis: The VALOR Study »A new review clarifies how the type of antibody driving cicatricial pemphigoid and related subepidermal blistering diseases influences both...
Read More — Antibody Class and Target Shape Disease Phenotype and Treatment in Cicatricial Pemphigoid and Related Conditions »A 2026 clinical practice review in the New England Journal of Medicine offers a comprehensive update on how to diagnose and manage polymyalg...
Read More — NEJM Clinical Practice Review: Polymyalgia Rheumatica Diagnosis and Management in Adults Over 50 »A landmark phase 3 trial found that obinutuzumab, a targeted anti-CD20 antibody, significantly outperformed placebo in reducing disease acti...
Read More — Obinutuzumab Achieves Superior Disease Control in Phase 3 ALLEGORY Trial for Systemic Lupus Erythematosus »Researchers have identified overlapping biological pathways between IgA nephropathy and celiac disease, two autoimmune conditions that frequ...
Read More — Shared Molecular Mechanisms and Diagnostic Markers Identified in IgA Nephropathy and Celiac Disease »